drugset

drugset / Trial / NCT01539473

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

NCT01539473 ↗

Phase 1 Completed 30 enrolled Merck & Co., Inc.

RandomizedSingle-groupDouble-blind

Summary

Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine

Timeline

Start: 2012-02
Primary completion: 2012-05
Completion: 2012-05

Publications

Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013 Jul;57(7):3060-6. doi: 10.1128/AAC.00431-13. Epub 2013 Apr 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tedizolid	Small molecule	200 mg	Oral
Background	Tyramine	Small molecule	—	Oral

Indications

No indication recorded.